Bioniche Life Sciences, Inc.

European patent granted for MCC in bladder cancer

Published in Health Insurance Law Weekly, May 1st, 2005

Bioniche Life Sciences, Inc., (BNC), a research-based, technology-driven human and animal health biopharmaceutical company, announced that it has had an additional European patent granted by the European Patent Office (EPO) on its core mycobacterial cell wall technology.

The patent relates to the company's proprietary product, Mycobacterial Cell Wall-DNA Complex (MCC), which has been shown to act as an immune stimulant and a chemotherapeutic agent. The new patent is:

"Treatment of Bladder Cancer by Mycobacterium phlei Cell Wall" (EP1054680B1), inventors Nigel C. Phillips and Mario C. Filion

"This latest patent further consolidates...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Health Insurance Law Weekly

Source: Health Insurance Law Weekly (2005-05-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry